The masthead
About CJC-1295 Ipamorelin: An Editorial Register of the Record
Who publishes this digest, what it is, and the lines it does not cross.
What this publication is
CJC-Ipa Chemical is a broadsheet register of what the peer-reviewed literature reports on CJC-1295 Ipamorelin — the research pairing of a long-acting GHRH analogue with a selective growth-hormone secretagogue. No clinic runs it and no clinician writes for it; it gives no medical advice, makes no product, and sells nothing. What it does is read publicly available science and report it on the record — stating what the literature establishes and marking, plainly, where it stops.
Why 'Chemical,' and what it does not mean
The "chemical" in our name is editorial framing — the position this publication occupies relative to a compound that exists, in practice, as a research chemical. It is not a claim that we supply, formulate, or sell anything. We carry no catalogue, take no orders, and quote no prices. Search traffic for this compound is heavy with vendor stand-ins; this site is the opposite of that — a sober technical account, written to be useful to a reader trying to understand the actual evidence rather than to buy a vial. The distinction between studied and extrapolated is the discipline this masthead is built around.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation in our references: a PubMed identifier or DOI for a real, published study. We hold a hard line between the two kinds of evidence that surround this compound. The first is controlled data on the single components — CJC-1295's documented multi-day GH and IGF-1 elevation, ipamorelin's selective GH release, the GHRH-plus-GHRP synergy work. The second is the much larger body of inference and anecdote about the fixed blend, which has never been tested in a controlled human trial. We report the first as evidence and label the second as what it is. Reported community effects are always marked anecdotal; mechanistic cautions are always marked theoretical.
What we do not do
We do not recommend that anyone use CJC-1295 Ipamorelin, and we publish no human dosing, preparation, or administration instructions. We do not employ or imply doctors, pharmacists, or any clinical staff, and we operate no consultation or treatment service. We do not use competitor brand names. Neither CJC-1295 nor ipamorelin is FDA-approved, and both are prohibited at all times for athletes under WADA Section S2 — facts we state because they are part of the record, not because we are advising for or against anything. This is a reading of the literature. It is not a prescription, and it is not a course of treatment.